MA
RPRX icon

Menlo Advisors’s Royalty Pharma RPRX Stock Holding History

Menlo Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$4.73M Sell
131,325
-1,910
-1% -$63.3K 2.55% 16
2025
Q1 		$4.15M Hold
133,235
– – 1.97% 18
2024
Q4 		$3.4M Sell
133,235
-14,650
-10% -$388K 1.73% 21
2024
Q3 		$4.18M Hold
147,885
– – 2.15% 18
2024
Q2 		$3.9M Buy
+147,885
New +$4.1M 2.16% 19

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

Menlo Advisors's RPRX Position: Q2 2025 in Review

Menlo Advisors reduced its Royalty Pharma (RPRX) stake by 1.4% in Q2 2025, selling an estimated $63.3K and leaving 131,325 shares worth $4.73M. The position accounts for 2.55% of the portfolio, ranked #16.

Menlo Advisors first reported a position in RPRX in Q2 2024 and has held it in 5 quarters since. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Menlo Advisors held 131,325 shares of Royalty Pharma worth $4.73M as of Q2 2025.
  • Menlo Advisors sold 1,910 Royalty Pharma shares in Q2 2025, an estimated $63.3K.
  • Royalty Pharma made up 2.55% of Menlo Advisors's portfolio in Q2 2025, its #16 holding.
  • Menlo Advisors first reported a position in Royalty Pharma in Q2 2024 and has held it in 5 quarters since.
  • 455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Menlo Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.